BMS/AZ’s Komboglyze A Non-Starter At IQWiG For Diabetes Type 2
This article was originally published in The Pink Sheet Daily
IQWiG of Germany has rejected Bristol/AstraZeneca’s Komboglyze for diabetes type 2 on procedural grounds, including use of the wrong comparator. The watchdog’s decision should induce manufacturers to negotiate early with health technology assessment bodies.
You may also be interested in...
Bristol-Myers Squibb is using a "new customer model" that takes a holistic approach to supporting Yervoy (ipilimumab), CEO Lamberto Andreotti told analysts on the company's first-quarter earnings call on April 28.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.